Pyxis Oncology, Inc.
PYXSHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. The $200.7M market capitalization puts PYXS squarely in micro-cap range for its industry. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Market Cap
$200.7M
Beta
1.38
P/E (TTM)
—
P/E (Fwd)
-1.52
EPS (TTM)
$-1.40
EPS (Fwd)
$-1.11
ROE
-179.1%
ROA
-62.9%
Cash
$33.0M
Total Debt
$17.8M
Free CF
-$23.2M
52W Change
-50.4%
Annual Financials
Cash vs Debt
Where PYXS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, PYXS finished 25.42% below its 150-day moving average ($2.36) and 18.14% below its 200-day moving average ($2.15). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PYXS overbought or oversold?
At the October 20, 2026 close, PYXS's RSI(14) was 14.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Pyxis Oncology, Inc. holds $33.0M in cash against $17.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$23.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -179.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PYXS.